ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Silencing of NLRP3 Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin

Li, Weijia; Zhao, Xibo; Zhang, Rujian; Xie, Jiabin; Zhang, Guangmei*南方医科大学; 哈尔滨医科大学; 1
Mediators of Inflammation2023-6-2DOI: 10.1155/2023/7700673
7阅读
引用收藏
分享

摘要

Background. Ovarian cancer is a fatal gynecological malignancy. The resistance to chemotherapy in ovarian cancer treatment has been a thorny issue. This study is aimed at probing the molecular mechanism of cisplatin (DDP) resistance in ovarian cancer. Methods. Bioinformatics analysis was conducted to examine the role of Nod-like receptor protein 3 (NLRP3) in ovarian cancer. The NLRP3 level in DDP-resistant ovarian cancer tumors and cell lines (SKOV3/DDP and A2780/DDP) was evaluated by applying immunohistochemical staining, western blot, and qRT-PCR. Cell transfection was conducted to regulate the NLRP3 level. Cell abilities to proliferate, migrate, invade, and apoptosis were measured employing colony formation, CCK-8, wound healing, transwell, and TUNEL assays, respectively. Cell cycle analysis was completed via flow cytometry. Corresponding protein expression was measured by western blot. Results. NLRP3 was overexpressed in ovarian cancer, correlated with poor survival, and upregulated in DDP-resistant ovarian cancer tumors and cells. NLRP3 silencing exerted antiproliferative, antimigrative, anti-invasive, and proapoptotic effects in A2780/DDP and SKOV3/DDP cells. Additionally, NLRP3 silencing inactivated NLRPL3 inflammasome and blocked epithelial-mesenchymal transition via enhancing E-cadherin and lowering vimentin, N-cadherin, and fibronectin. Conclusion. NLRP3 was overexpressed in DDP-resistant ovarian cancer. NLRP3 knockdown hindered the malignant process of DDP-resistant ovarian cancer cells, providing a potential target for DPP-based ovarian cancer chemotherapy.

学科与关键词

关键词
EPITHELIAL-MESENCHYMAL TRANSITIONRESISTANCEINFLAMMASOMECHEMOTHERAPY
相关
加载中…
  • Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine
    Guo, Chong; Song, Chaoying; Zhang, Jiali; Gao, Yisong; Qi, Yuying; Zhao, Zongyao; Yuan, Chengfu*Genes & Diseases, 2022, 9(3): 668-681.被引 10
  • Circular RNA CDR1as Alleviates Cisplatin-Based Chemoresistance by Suppressing MiR-1299 in Ovarian Cancer
    Wu, Han; Zhao, Xibo; Wang, Jing; Jiang, Xinyan; Cheng, Yan; He, Yanan; Sun, Liyuan; Zhang, Guangmei*Frontiers in Genetics, 2022, 12: 815448.被引 6
  • Aberrant epigenetic regulation of FZD3 by TET2 is involved in ovarian cancer cell resistance to cisplatin
    Zhu, Li; Zhou, Qian*JOURNAL OF CHEMOTHERAPY, 2023.
查看全部 →

发表信息

论文状态
公开发表
期刊
Mediators of Inflammation
发表日期
2023-06-02
卷期
第 2023 卷
页码
7700673
DOI
10.1155/2023/7700673
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81772780]

作者

  • L

    Li, Weijia (第一作者)

    harbin med univ

  • Z

    Zhao, Xibo

    1 · harbin med univ

查看全部 5 位作者收起作者
  • Z

    Zhang, Rujian

    southern med univ

  • X

    Xie, Jiabin

    southern med univ

  • Z

    Zhang, Guangmei (通讯)

    1 · harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417